Skip to main content
Equibles
IRMD logo

IRMD · Iradimed Corp · Metrics

Track IRMD — free

Use IRMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IRMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$83.95 -0.68 (-0.80%) At close · Oct 27 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.08B
Shares
12.79M
Volume · Oct 27 127.15K Avg daily vol (3M) 123.45K

IRMD metrics

116 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$83.95
Market cap
$1.08B

Price action

20 metrics
Price change (1W)
-3.4%
Price change (30D)
-2.3%
Price change (3M)
-11.0%
Price change (6M)
-5.0%
Price change (YTD)
-13.0%
Price change (1Y)
+7.9%
Trailing year
Price change (5Y)
+137.9%
52-week high
$105.15
52-week low
$76.42
Change from 52-week high
-19.5%
Change from 52-week low
+10.7%
Annualized volatility
30.0%
Annualized volatility (3M)
21.9%
Beta
0.6
RSI (14D)
39.7
Price vs SMA 50
-1.6%
Price vs SMA 200
-8.9%
Avg volume (3M)
122,532
Relative volume
1.5
Average dollar volume
$10.68M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
12.79M

Valuation

12 metrics
P / E (TTM)
47.3
Trailing earnings · reciprocal yield 2.1%
PEG ratio
—
EV / revenue
12.0×
reciprocal yield 8.3%
EV / EBITDA
35.6×
reciprocal yield 2.8%
EV / EBIT
37.7×
reciprocal yield 2.7%
P / sales
12.7×
reciprocal yield 7.9%
P / book
10.8
reciprocal yield 9.3%
FCF yield
2.3%
TTM · current market cap
Buyback yield
—
P / FCF
43.7
reciprocal yield 2.3%
P / operating cash flow
40.4
reciprocal yield 2.5%
Earnings yield
2.1%

Historical valuation

8 metrics
P / E historical average (3Y)
40.0×
reciprocal yield 2.5%
P / E historical average (5Y)
45.2×
reciprocal yield 2.2%
EV / revenue historical average (3Y)
9.8×
reciprocal yield 10.2%
EV / revenue historical average (5Y)
9.6×
reciprocal yield 10.4%
EV / EBIT historical average (3Y)
31.8×
reciprocal yield 3.1%
EV / EBIT historical average (5Y)
35.5×
reciprocal yield 2.8%
EV / EBITDA historical average (3Y)
30.3×
reciprocal yield 3.3%
EV / EBITDA historical average (5Y)
32.3×
reciprocal yield 3.1%

Dividends & buybacks

7 metrics
Dividend yield
1.5%
Trailing 12 months
Payout ratio
68.7%
Shareholder yield
1.4%
Dividend / share (TTM)
$1.27
Dividend growth YoY
+92.4%
Dividend growth streak
1
Last ex-dividend
2026-08-14

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-31

Profitability

9 metrics
Gross margin
75.9%
Operating margin
31.9%
Trailing 12 months
Net margin
26.7%
Gross profit (TTM)
$65.50M
Operating profit (TTM)
$27.55M
Net income (TTM)
$23.05M
Trailing 12 months
Diluted EPS (TTM)
$1.79
FCF margin
29.1%
Effective tax rate
22.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$6.71
Gross profit per diluted share (TTM)
$5.09
Operating profit per diluted share (TTM)
$2.14
EBITDA per diluted share (TTM)
$2.27
Net income per diluted share (TTM)
$1.79
Operating cash flow per diluted share (TTM)
$2.11
Free cash flow per diluted share (TTM)
$1.95
Capital expenditures per diluted share (TTM)
$0.16
R&D per diluted share (TTM)
$0.24
Stock compensation per diluted share (TTM)
$0.22
Book value per share
$7.40

Growth

11 metrics
Revenue growth YoY
+0.3%
Year over year
Net income growth YoY
-9.6%
Revenue (TTM)
$86.34M
Trailing 12 months
EPS growth YoY
-8.9%
Shares change YoY
+0.3%
Year over year · more shares
Revenue CAGR (3Y)
+16.3%
Revenue CAGR (5Y)
+21.5%
EPS CAGR (3Y)
+19.7%
EPS CAGR (5Y)
+73.9%
FCF CAGR (3Y)
+23.1%
FCF CAGR (5Y)
+26.2%

Quality

14 metrics
Return on equity
22.7%
Return on assets
20.1%
Debt / equity
0.0
Current ratio
9.5
EBITDA (TTM)
$29.18M
Free cash flow (TTM)
$25.12M
Quick ratio
8.1
Interest coverage
—
Net debt / EBITDA
-2.0
Return on invested capital
50.1%
Trailing 12 months
Net cash
$59.08M
Latest balance sheet
Cash & equivalents
$59.08M
Total assets
$114.97M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$27.14M
Capital expenditures (TTM)
$2.02M
R&D (TTM)
$3.09M
SG&A (TTM)
—
Stock compensation (TTM)
$2.85M
R&D / revenue
3.6%
Stock compensation / revenue
3.3%

Ownership (13F)

9 metrics
13F filers
215
13F filer change QoQ
-13
Institutional ownership
61.6%
Conviction holders (share of 13F filers)
0.9%
Crowding (high-turnover and private-fund holders)
17.9%
Private-fund adviser ownership
17.2%
Active holders' share change QoQ
+3.5%
Holder tenure
13.5
Price vs estimated holder cost
+33.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.7%

Short interest

3 metrics
Short interest
5.2%
Latest settlement · 6.2 days to cover
Days to cover
6.2d
Short-squeeze score
62 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$122,622
Insider-sentiment score
48 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1325618 CUSIP 46266A109 13F (30d) 43 filings 38 filers Visit website Investor relations